CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 81 enrolled
Drug / intervention
Morphine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03249558
NCT03249558Phase 4Completed
CompareCT.gov

Effect of Combined Morphine and Duloxetine on Chronic Pain

Massachusetts General Hospital·interventional·Posted Aug 15, 2017·Updated Nov 14, 2024

In Brief

A Phase 4 clinical trial evaluating Morphine, Duloxetine, and 1 other intervention for Chronic Low Back Pain and Chronic Neck Pain. Completed, enrolled 81 participants across 1 site.

Detailed Summary

A double-blind, randomized, and placebo-controlled clinical study examining whether duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), could enhance opioid analgesia and reduce overall opioid use. Positive outcomes will help improve the overall effectiveness of clinical opioid therapy and reduce unnecessary opioid dose escalation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Low Back Pain, Chronic Neck Pain
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 15, 2017
Enrollment StartMar 12, 2018
Primary CompletionApr 5, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.9 years ago

Interventions

Morphinedrug

Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Duloxetinedrug

Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.

Placebodrug

Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.